BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 30558725)

  • 1. Circulating Tumor Cells and Cell-Free DNA in Pancreatic Ductal Adenocarcinoma.
    Gall TMH; Belete S; Khanderia E; Frampton AE; Jiao LR
    Am J Pathol; 2019 Jan; 189(1):71-81. PubMed ID: 30558725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liquid biopsy in pancreatic ductal adenocarcinoma: current status of circulating tumor cells and circulating tumor DNA.
    Lee JS; Park SS; Lee YK; Norton JA; Jeffrey SS
    Mol Oncol; 2019 Aug; 13(8):1623-1650. PubMed ID: 31243883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant
    Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
    Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer.
    Riva F; Dronov OI; Khomenko DI; Huguet F; Louvet C; Mariani P; Stern MH; Lantz O; Proudhon C; Pierga JY; Bidard FC
    Mol Oncol; 2016 Mar; 10(3):481-93. PubMed ID: 26856794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can circulating tumor and exosomal nucleic acids act as biomarkers for pancreatic ductal adenocarcinoma?
    Liu DSK; Mato Prado M; Giovannetti E; Jiao LR; Krell J; Frampton AE
    Expert Rev Mol Diagn; 2019 Jul; 19(7):553-558. PubMed ID: 31159604
    [No Abstract]   [Full Text] [Related]  

  • 6. KRAS mutations in blood circulating cell-free DNA: a pancreatic cancer case-control.
    Le Calvez-Kelm F; Foll M; Wozniak MB; Delhomme TM; Durand G; Chopard P; Pertesi M; Fabianova E; Adamcakova Z; Holcatova I; Foretova L; Janout V; Vallee MP; Rinaldi S; Brennan P; McKay JD; Byrnes GB; Scelo G
    Oncotarget; 2016 Nov; 7(48):78827-78840. PubMed ID: 27705932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma circulating tumor DNA in pancreatic adenocarcinoma for screening, diagnosis, prognosis, treatment and follow-up: A systematic review.
    Abdallah R; Taly V; Zhao S; Pietrasz D; Bachet JB; Basile D; Mas L; Zaanan A; Laurent-Puig P; Taieb J
    Cancer Treat Rev; 2020 Jul; 87():102028. PubMed ID: 32485509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of circulating tumor DNA without a tumor-informed search using next-generation sequencing is a prognostic biomarker in pancreatic ductal adenocarcinoma.
    Affolter KE; Hellwig S; Nix DA; Bronner MP; Thomas A; Fuertes CL; Hamil CL; Garrido-Laguna I; Scaife CL; Mulvihill SJ; Underhill HR
    Neoplasia; 2021 Sep; 23(9):859-869. PubMed ID: 34298235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved Assessment of Response Status in Patients with Pancreatic Cancer Treated with Neoadjuvant Therapy using Somatic Mutations and Liquid Biopsy Analysis.
    Yin L; Pu N; Thompson E; Miao Y; Wolfgang C; Yu J
    Clin Cancer Res; 2021 Feb; 27(3):740-748. PubMed ID: 33082211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer.
    Patel H; Okamura R; Fanta P; Patel C; Lanman RB; Raymond VM; Kato S; Kurzrock R
    J Hematol Oncol; 2019 Dec; 12(1):130. PubMed ID: 31801585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer.
    Earl J; Garcia-Nieto S; Martinez-Avila JC; Montans J; Sanjuanbenito A; Rodríguez-Garrote M; Lisa E; Mendía E; Lobo E; Malats N; Carrato A; Guillen-Ponce C
    BMC Cancer; 2015 Oct; 15():797. PubMed ID: 26498594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative monitoring of circulating tumor DNA in patients with advanced pancreatic cancer undergoing chemotherapy.
    Sugimori M; Sugimori K; Tsuchiya H; Suzuki Y; Tsuyuki S; Kaneta Y; Hirotani A; Sanga K; Tozuka Y; Komiyama S; Sato T; Tezuka S; Goda Y; Irie K; Miwa H; Miura Y; Ishii T; Kaneko T; Nagahama M; Shibata W; Nozaki A; Maeda S
    Cancer Sci; 2020 Jan; 111(1):266-278. PubMed ID: 31746520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring the Clinical Utility of Pancreatic Cancer Circulating Tumor Cells.
    Yeo D; Bastian A; Strauss H; Saxena P; Grimison P; Rasko JEJ
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SST gene hypermethylation acts as a pan-cancer marker for pancreatic ductal adenocarcinoma and multiple other tumors: toward its use for blood-based diagnosis.
    Manoochehri M; Wu Y; Giese NA; Strobel O; Kutschmann S; Haller F; Hoheisel JD; Moskalev EA; Hackert T; Bauer AS
    Mol Oncol; 2020 Jun; 14(6):1252-1267. PubMed ID: 32243066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Utility of Circulating Tumor DNA for Molecular Assessment and Precision Medicine in Pancreatic Cancer.
    Takai E; Totoki Y; Nakamura H; Kato M; Shibata T; Yachida S
    Adv Exp Med Biol; 2016; 924():13-17. PubMed ID: 27753011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multianalyte Prognostic Signature Including Circulating Tumor DNA and Circulating Tumor Cells in Patients With Advanced Pancreatic Adenocarcinoma.
    Chapin WJ; Till JE; Hwang WT; Eads JR; Karasic TB; O'Dwyer PJ; Schneider CJ; Teitelbaum UR; Romeo J; Black TA; Christensen TE; Redlinger Tabery C; Anderson A; Slade M; LaRiviere M; Yee SS; Reiss KA; O'Hara MH; Carpenter EL
    JCO Precis Oncol; 2022 Jul; 6():e2200060. PubMed ID: 35939771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating tumor cells found in patients with localized and advanced pancreatic cancer.
    Kulemann B; Pitman MB; Liss AS; Valsangkar N; Fernández-Del Castillo C; Lillemoe KD; Hoeppner J; Mino-Kenudson M; Warshaw AL; Thayer SP
    Pancreas; 2015 May; 44(4):547-50. PubMed ID: 25822154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of Hot-Spot Mutations in Circulating Cell-Free DNA From Patients With Intraductal Papillary Mucinous Neoplasms of the Pancreas.
    Berger AW; Schwerdel D; Costa IG; Hackert T; Strobel O; Lam S; Barth TF; Schröppel B; Meining A; Büchler MW; Zenke M; Hermann PC; Seufferlein T; Kleger A
    Gastroenterology; 2016 Aug; 151(2):267-70. PubMed ID: 27343369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KRAS mutations in pancreatic circulating tumor cells: a pilot study.
    Kulemann B; Liss AS; Warshaw AL; Seifert S; Bronsert P; Glatz T; Pitman MB; Hoeppner J
    Tumour Biol; 2016 Jun; 37(6):7547-54. PubMed ID: 26684803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular detection of epithelial-mesenchymal transition markers in circulating tumor cells from pancreatic cancer patients: Potential role in clinical practice.
    Zhao XH; Wang ZR; Chen CL; Di L; Bi ZF; Li ZH; Liu YM
    World J Gastroenterol; 2019 Jan; 25(1):138-150. PubMed ID: 30643364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.